Fumagillin

Fumagillin

SCHEMBL6953272

COC1C(OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)CCC2(CO2)C1C1(C)OC1CC=C(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 18/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
MEN1 O00255 1/20 1.00
ALDH1A1 P00352 1/20 1.00
MAPT P10636 1/20 1.00
KMT2A Q03164 1/20 1.00
CYP3A4 P08684 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumagillin SCHEMBL13819097 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL8130 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL18517986 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL17959149 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL12526078 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL18517793 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL15263951 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL13304359 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL15745869 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1
Fumagillin SCHEMBL18517985 1.00 METAP2 (1.00) METAP2ABCB11LMNAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-06-22 US disclosed
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-06-22 US disclosed
US-20210299253-A1 NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME PROTECH CO., LTD. (KR) 2021-09-30 US disclosed
US-10406134-B2 Methods of treating an overweight subject ZAFGEN, INC. (US) 2019-09-10 US disclosed
US-20190224156-A1 Methods of Treating an Overweight or Obese Subject ZAFGEN INC (US) 2019-07-25 US disclosed
US-20190022051-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN INC (US) 2019-01-24 US disclosed
US-9925166-B2 Methods of treating an overweight or obese subject ZAFGEN, INC. (US) 2018-03-27 US disclosed
US-9925166-B2 Methods of treating an overweight or obese subject ZAFGEN, INC. (US) 2018-03-27 US disclosed
US-20180064677-A1 Methods of Treating an Overweight or Obese Subject ZAFGEN INC (US) 2018-03-08 US disclosed
US-20180055811-A1 METHODS OF TREATING AN OVERWEIGHT SUBJECT VANDERBILT UNIVERSITY (US) 2018-03-01 US disclosed
US-20100184853-A1 TERPENES WITH ANTIFUNGAL ACTIVITY AGAINST MALASSEZIA YEASTS INSTITUTO BIOMAR, S.A. (ES) 2010-07-22 US disclosed
WO-2010065883-A2 METHOD OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN CORPORATION (US) 2010-06-10 WO disclosed
WO-2010009374-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN, INC. (US) 2010-01-21 WO disclosed
US-20100016425-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN, INC. (US) 2010-01-21 US disclosed
US-20100016425-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN, INC. (US) 2010-01-21 US disclosed
WO-2008152127-A1 TERPENES WITH ANTIFUNGAL ACTIVITY AGAINST MALASSEZIA YEASTS INSTITUTO BIOMAR, S.A. (ES) 2008-12-18 WO disclosed
US-20080200402-A1 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2008-08-21 US disclosed
US-20080200402-A1 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2008-08-21 US disclosed
WO-2006131649-A2 USE OF FUMAGILLIN AND THE DERIVATIVES THEREOF TO INCREASE THE BIOAVAILABILITY OF THE MACROCYCLIC LACTONES INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2006-12-14 WO disclosed
US-6528539-B1 And propylene glycol dicaprate/dicaprylate hydrophobic agent SANOFI-SYNTHELABO (FR) 2003-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200402-A1 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones ABCB1, SLC47A1, ABCC1 METAP2 3141/4885ABCB11 4/4885LMNA 1924/4885
US-20180055811-A1 METHODS OF TREATING AN OVERWEIGHT SUBJECT METAP2, CPT1B, SLC5A2 METAP2 1/4885ABCB11 1980/4885LMNA 3061/4885
US-10406134-B2 Methods of treating an overweight subject METAP2, CPT1B, SLC5A2 METAP2 1/4885ABCB11 1980/4885LMNA 3061/4885
US-20100016425-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT LIPC, FABP4, LPL METAP2 777/4885ABCB11 118/4885LMNA 1627/4885
US-20230190938-A1 NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME ATG7, SQSTM1, BECN1 METAP2 3678/4885ABCB11 419/4885LMNA 1560/4885
US-20180064677-A1 Methods of Treating an Overweight or Obese Subject METAP2, ADIPOR2, FABP4 METAP2 1/4885ABCB11 4284/4885LMNA 4501/4885
US-20100184853-A1 TERPENES WITH ANTIFUNGAL ACTIVITY AGAINST MALASSEZIA YEASTS CYP51A1, ERG28, DPM1 METAP2 2908/4885ABCB11 411/4885LMNA 3866/4885
US-20190022051-A1 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT LIPC, FABP4, LPL METAP2 777/4885ABCB11 118/4885LMNA 1627/4885
US-20190224156-A1 Methods of Treating an Overweight or Obese Subject METAP2, ADIPOR2, FABP4 METAP2 1/4885ABCB11 4284/4885LMNA 4501/4885
US-20210299253-A1 NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME ATG7, SQSTM1, CTSA METAP2 1840/4885ABCB11 2313/4885LMNA 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.